Oncology

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

10/30/2025

No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Excerpt from the Press Release: NEW YORK–(BUSINESS WIRE)– Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges…

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

10/28/2025

Excerpt from the Press Release: FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis’ highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a useful tool in assessing the maintenance…

ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection

10/27/2025

Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study…

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

10/24/2025

Excerpt from the Press Release: BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.…

Frontier Medicines Announces Third Precision Oncology Development Candidate

10/22/2025

Excerpt from the Press Release: BOSTON and SOUTH SAN FRANCISCO, Calif. (October 14, 2025) – Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule, precision oncology and immunology drugs against previously undruggable disease-causing targets, today announced its latest development candidate. FMC-242 is a covalent allosteric inhibitor that breaks the interaction…

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

10/21/2025

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor…

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

10/20/2025

The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the…

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

10/17/2025

Excerpt from the Press Release: BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and…

RefleXion Announces First Patient Treatment at Leading Freestanding Cancer Center

10/15/2025

Beverly Hills Cancer Center expands patient treatment options in Southern California Excerpt from the Press Release: HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion, an external-beam, theranostic oncology company, today announced that Beverly Hills Cancer Center, a leading private cancer diagnostic and treatment facility, has treated its first patient with the RefleXion® X1 dual-treatment modality radiotherapy platform. This milestone marks…

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

09/08/2025

Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are…